Friday - March 20, 2026

Glioma Pipeline Expands as 180+ Pharma Companies Advance Several Novel Therapies, Finds DelveInsight | Aivita Biomedical, Denovo BioPharma, Medicenna Therapeutics, Eli Lilly, Candel Therapeutics

Glioma – Pipeline Insight, 2026 DelveInsight’s “Glioma – Pipeline Insight, 2026” report provides comprehensive insights about 180+ companies, including Aivita Biomedical, Inc., Denovo BioPharma, Medicenna Therapeutics, Inc., Eli Lilly and Company, Candel Therapeutics, Mustang Bio, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, … Continue reading

Cutaneous Squamous Cell Carcinoma Pipeline Grows as 45+ Pharma Companies Advance Novel Skin Cancer Therapies, Finds DelveInsight | Incyte, Shanghai Henlius Biotech, Novartis, Rakuten Medical, Roche, G

Cutaneous Squamous Cell Carcinoma (CSCC) – Pipeline Insight, 2026 DelveInsight’s “Cutaneous Squamous Cell Carcinoma (CSCC) – Pipeline Insight, 2026” report provides comprehensive insights about 45+ companies, such as Incyte Corporation, Shanghai Henlius Biotech, Novartis, Rakuten Medical, Morphogenesis, Genentech, Berg Pharma, … Continue reading

Telehealth Market Poised for Exceptional Growth at 31.81% CAGR Through 2034: DelveInsight | Teladoc Health, Koninklijke Philips N.V., and Siemens Healthineers

Global Telehealth Market Insights Key global players include Teladoc Health, Inc., Siemens Healthineers AG, Cisco Systems, Inc., Koninklijke Philips N.V., IBM Corporation, Medtronic, American Well Corporation, CareCloud, Inc., GlobalMed Holding LLC., Doctor On Demand by Included Health, Inc., derma2go Deutschland … Continue reading

Fuchs Endothelial Corneal Dystrophy Clinical Trial Pipeline Accelerates as 5+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s “Fuchs Endothelial Corneal Dystrophy Pipeline Insight 2026” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Fuchs Endothelial Corneal Dystrophy pipeline landscape. It covers the Fuchs Endothelial Corneal Dystrophy pipeline drug profiles, including clinical and … Continue reading

Breast Cancer Clinical Trial Gains Momentum: 250+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s “Breast Cancer Pipeline Insight 2026” report provides comprehensive insights about 250+ Breast Cancer companies and 300+ pipeline drugs in the Breast Cancer pipeline landscape. It covers the Breast Cancer pipeline drugs profiles, including clinical and nonclinical stage products. It … Continue reading

Wet-Age Related Macular Degeneration Treatment Pipeline Shows Strong Momentum as 60+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “Wet-AMD Pipeline Insight 2026” report provides comprehensive insights about 60+ companies and 75+ pipeline drugs in the Wet-AMD pipeline landscape. It covers the Wet-AMD Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Wet-AMD Pipeline … Continue reading

Dravet Syndrome Clinical Trial Pipeline Shows Potential with Active Contributions from 10+ Key Companies | DelveInsight

DelveInsight’s, “Dravet syndrome Pipeline Insight 2026” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Dravet syndrome pipeline landscape. It covers the Dravet Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading

Malignant Ascites Clinical Trial Pipeline Gains Momentum: 5+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

elveInsight’s, “Malignant Ascites Pipeline Insights 2026” Report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Malignant Ascites pipeline landscape. It covers the Malignant Ascites pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading

Triple Negative Breast Cancer Clinical Trial Pipeline Expands as 165+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “Triple Negative Breast Cancer Pipeline Insight 2026” report provides comprehensive insights about 165+ companies and 170+ pipeline drugs in the Triple Negative Breast Cancer pipeline landscape. It covers the Triple Negative Breast Cancer Pipeline drug profiles, including clinical and … Continue reading

High-Grade Glioma Treatment Pipeline Shows Strong Momentum as 150+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “High-Grade Glioma Pipeline Insight 2026” report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the High-Grade Glioma pipeline landscape. It covers the High-Grade Glioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading